CO6351797A2 - Formas solidas de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibencil) fenil)-o-(metiltio) tetrahidro-2h-piran- 3,4,5-triol y metodos para su uso - Google Patents
Formas solidas de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibencil) fenil)-o-(metiltio) tetrahidro-2h-piran- 3,4,5-triol y metodos para su usoInfo
- Publication number
- CO6351797A2 CO6351797A2 CO11014849A CO11014849A CO6351797A2 CO 6351797 A2 CO6351797 A2 CO 6351797A2 CO 11014849 A CO11014849 A CO 11014849A CO 11014849 A CO11014849 A CO 11014849A CO 6351797 A2 CO6351797 A2 CO 6351797A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- triol
- phenyl
- tetrahydro
- solid forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Esta invención se dirige, en parte, a formas sólidas amorfas y cristalinas de (2S,3R,4R,5S,6R)-2-(4-cloro-3-(4-etoxibencil) fenil)-6-(metiltio) tetrahidro-2H- piran-3,4,5-triol anhidro, que es un inhibidor del co-transportador de glucosa sodio tipo 2, y puede ser útil en el tratamiento de diabetes y una variedad de otras enfermedades y afecciones. Esta invención también se dirige a formas de dosificación que comprenden formas sólidas de (2S,3R,4R,5S,6R)-2-(4-cloro-3-(4-etoxibencil)fenil)-6- (metiltio) tetrahidro-2H-piran-3,4,5-triol anhidro, y con métodos para su uso.Una modalidad de la invención abarca las composiciones farmacéuticas que comprenden las formas sólidas descritas aquí.Otra modalidad abarca métodos para inhibir la actividad SGLT2, así como también métodos para tratar, prevenir y manejar una variedad de enfermedades y trastornos, utilizando las formas sólidas descritas aquí.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8142308P | 2008-07-17 | 2008-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6351797A2 true CO6351797A2 (es) | 2011-12-20 |
Family
ID=41137707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11014849A CO6351797A2 (es) | 2008-07-17 | 2011-02-09 | Formas solidas de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibencil) fenil)-o-(metiltio) tetrahidro-2h-piran- 3,4,5-triol y metodos para su uso |
Country Status (29)
Country | Link |
---|---|
US (2) | US8217156B2 (es) |
EP (1) | EP2332947B1 (es) |
JP (2) | JP2011528366A (es) |
KR (2) | KR20170010069A (es) |
CN (2) | CN102112483A (es) |
AR (1) | AR072807A1 (es) |
AU (1) | AU2009270973B2 (es) |
BR (1) | BRPI0916191A2 (es) |
CA (1) | CA2730931A1 (es) |
CL (1) | CL2009001595A1 (es) |
CO (1) | CO6351797A2 (es) |
DK (1) | DK2332947T3 (es) |
ES (1) | ES2656357T3 (es) |
HK (1) | HK1243713A1 (es) |
HU (1) | HUE035400T2 (es) |
IL (1) | IL210269A (es) |
MX (1) | MX2011000503A (es) |
NO (1) | NO2332947T3 (es) |
NZ (1) | NZ590184A (es) |
PE (1) | PE20100260A1 (es) |
PL (1) | PL2332947T3 (es) |
PT (1) | PT2332947T (es) |
RU (1) | RU2505543C2 (es) |
SG (1) | SG185317A1 (es) |
TW (1) | TWI472521B (es) |
UA (1) | UA106048C2 (es) |
UY (1) | UY31992A (es) |
WO (1) | WO2010009197A1 (es) |
ZA (1) | ZA201100175B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
PT2183263E (pt) * | 2007-07-26 | 2012-01-11 | Lexicon Pharmaceuticals Inc | Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio |
BRPI0916769A2 (pt) | 2008-07-15 | 2017-09-26 | Theracos Inc | derivados de benzilbenzeno deuterados e métodos de uso |
TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法 |
TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
CN102453026A (zh) | 2010-10-27 | 2012-05-16 | 上海艾力斯医药科技有限公司 | C-芳基葡糖苷衍生物、制备方法及其应用 |
TWI631963B (zh) * | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9200025B2 (en) | 2012-11-20 | 2015-12-01 | Lexicon Pharmaceuticals, Inc. | Inhibitors of sodium glucose cotransporter 1 |
CA2922044A1 (en) | 2013-10-18 | 2015-05-14 | Medivation Technologies, Inc. | Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk) |
CA2922058A1 (en) | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
CA2993425A1 (en) | 2015-07-30 | 2017-02-02 | Microbial Chemistry Research Foundation | Effective aminoglycoside antibiotic for multidrug-resistant bacteria |
EP3466958B1 (en) * | 2016-05-25 | 2020-04-29 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | New crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof |
WO2018067805A1 (en) | 2016-10-06 | 2018-04-12 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sotagliflozin |
EP3528800A1 (en) | 2016-10-19 | 2019-08-28 | Boehringer Ingelheim International GmbH | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
JP2021520394A (ja) | 2018-04-17 | 2021-08-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物、処置方法及びその使用 |
CN110818722B (zh) * | 2018-08-14 | 2022-12-02 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
SG11202102498UA (en) * | 2018-09-26 | 2021-04-29 | Lexicon Pharmaceuticals Inc | Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis |
CN109824687B (zh) * | 2019-03-26 | 2022-03-22 | 上海凌凯医药科技有限公司 | 呋喃木糖衍生物的新合成方法 |
AU2020310274B2 (en) * | 2019-07-05 | 2022-09-29 | Shandong Danhong Pharmaceutical Co., Ltd. | Crystal form of SGLT inhibitor and application thereof |
EP3771718A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Process for preparing the crystalline form ii of sotagliflozin |
EP3771480A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
WO2022144465A1 (en) | 2021-01-04 | 2022-07-07 | Charité-Universitätsmedizin Berlin | Sotagliflozin for improving left atrial function |
WO2022155303A1 (en) | 2021-01-14 | 2022-07-21 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for treating or preventing cardiovascular diseases |
CN113880701A (zh) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | 一种抗糖尿病药物中间体及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870699A (en) * | 1973-03-06 | 1975-03-11 | Upjohn Co | Lincomycin analogs |
JP2003519698A (ja) * | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ,インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
DE602006009772D1 (de) | 2005-02-23 | 2009-11-26 | Boehringer Ingelheim Int | Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2) |
CN1820858A (zh) * | 2006-03-10 | 2006-08-23 | 广西中医学院制药厂 | 多相物料喷雾方法及装置 |
TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
PT2183263E (pt) * | 2007-07-26 | 2012-01-11 | Lexicon Pharmaceuticals Inc | Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio |
TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法 |
-
2009
- 2009-07-01 TW TW98122274A patent/TWI472521B/zh active
- 2009-07-15 PL PL11155100T patent/PL2332947T3/pl unknown
- 2009-07-15 BR BRPI0916191A patent/BRPI0916191A2/pt not_active Application Discontinuation
- 2009-07-15 CN CN2009801279245A patent/CN102112483A/zh active Pending
- 2009-07-15 KR KR1020177001061A patent/KR20170010069A/ko not_active Application Discontinuation
- 2009-07-15 ES ES11155100.8T patent/ES2656357T3/es active Active
- 2009-07-15 CA CA2730931A patent/CA2730931A1/en not_active Abandoned
- 2009-07-15 PE PE2009000944A patent/PE20100260A1/es not_active Application Discontinuation
- 2009-07-15 CL CL2009001595A patent/CL2009001595A1/es unknown
- 2009-07-15 EP EP11155100.8A patent/EP2332947B1/en active Active
- 2009-07-15 NZ NZ590184A patent/NZ590184A/xx unknown
- 2009-07-15 KR KR1020117001024A patent/KR101707246B1/ko active IP Right Grant
- 2009-07-15 SG SG2012077681A patent/SG185317A1/en unknown
- 2009-07-15 MX MX2011000503A patent/MX2011000503A/es active IP Right Grant
- 2009-07-15 HU HUE11155100A patent/HUE035400T2/en unknown
- 2009-07-15 NO NO11155100A patent/NO2332947T3/no unknown
- 2009-07-15 JP JP2011518868A patent/JP2011528366A/ja active Pending
- 2009-07-15 DK DK11155100.8T patent/DK2332947T3/da active
- 2009-07-15 WO PCT/US2009/050636 patent/WO2010009197A1/en active Application Filing
- 2009-07-15 UA UAA201101832A patent/UA106048C2/uk unknown
- 2009-07-15 US US12/503,225 patent/US8217156B2/en active Active
- 2009-07-15 PT PT111551008T patent/PT2332947T/pt unknown
- 2009-07-15 RU RU2011105797/04A patent/RU2505543C2/ru active
- 2009-07-15 AR ARP090102685A patent/AR072807A1/es unknown
- 2009-07-15 AU AU2009270973A patent/AU2009270973B2/en active Active
- 2009-07-15 CN CN201710477527.7A patent/CN107629097A/zh not_active Withdrawn
- 2009-07-16 UY UY0001031992A patent/UY31992A/es not_active Application Discontinuation
-
2010
- 2010-12-26 IL IL210269A patent/IL210269A/en active IP Right Grant
-
2011
- 2011-01-06 ZA ZA2011/00175A patent/ZA201100175B/en unknown
- 2011-02-09 CO CO11014849A patent/CO6351797A2/es not_active Application Discontinuation
-
2012
- 2012-06-22 US US13/530,645 patent/US9067962B2/en active Active
-
2015
- 2015-09-30 JP JP2015193990A patent/JP6283337B2/ja active Active
-
2018
- 2018-03-02 HK HK18103068.1A patent/HK1243713A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6351797A2 (es) | Formas solidas de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibencil) fenil)-o-(metiltio) tetrahidro-2h-piran- 3,4,5-triol y metodos para su uso | |
AR084781A1 (es) | Composiciones que comprenden y metodos que utilizan inhibidores de los cotransportadores de sodio-glucosa 1 y 2 | |
PA8840801A1 (es) | Derivaos de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
EA201391651A1 (ru) | Сокристаллы l-пролина и лимонной кислоты (2s,3r,4r,5s,6r)-2-(3-((5-(4-фторфенил)тиофен-2-ил)метил)-4-метилфенил)-6-(гидроксиметил)тетрагидро-2h-пиран-3,4,5-триол | |
CY1119810T1 (el) | Παραγωγα(2s,3r,4r,5s,6r)-2-(4-χλωρο-3-βενζυλφαινυλ)-6-(υδροξυμεθυλ)τετραϋδρο-2h-πυραν-3,4,5-τριολης για χρηση στη θεραπεια του διαβητη | |
NZ595382A (en) | Combination therapy involving n-(5-(tert-butyl-isoxazol-3-yl)-n’-{ 4-(7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl} urea | |
NO20075111L (no) | Farmasoytisk sammensetning | |
EA201290267A1 (ru) | Производные диоксабицикло[3.2.1]октан-2,3,4-триола | |
AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
BRPI0609424B8 (pt) | composto inibidor da dipeptidil peptidase-iv e composição farmacêutica compreendendo dito composto como um agente ativo | |
BRPI0813450B8 (pt) | composto, formulação farmacêutica, e, usos do composto | |
EA201101190A1 (ru) | Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
UA108887C2 (xx) | Кристалічна форма бензил-бензольного інгібітора sglt2 | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
CR9782A (es) | Composiciones de carbohidratos obtenidas a partir de hongos basidiomicetes para ser utilizadas como agentes biocidas contra patogenos | |
AR081082A1 (es) | Composiciones organicas para tratar enfermedades relacionadas con beta-enac | |
AR055658A1 (es) | Composiciones fungicidas | |
BRPI0507745A (pt) | compostos de azetidina substituìda como inibidores de ciclooxigenase-1-ciclooxigenase-2, processo para a sua preparação, medicamentos e seus usos | |
TH122363A (th) | รูปแบบที่เป็นของแข็งของ (2s, 3r, 4r, 5s, 6r)-2-(4-คลอโร-3-(4-เอทธอกซีเบนซิล)-ฟีนิล)-6-(เมทธิลไธโอ)เตตราไฮโดร-2-h-ไพราน-3,4,5-ไตรออล และวิธีการของการใช้สิ่งเหล่านี้ | |
TH122363B (th) | รูปแบบที่เป็นของแข็งของ (2s, 3r, 4r, 5s, 6r)-2-(4-คลอโร-3-(4-เอทธอกซีเบนซิล)-ฟีนิล)-6-(เมทธิลไธโอ)เตตราไฮโดร-2-h-ไพราน-3,4,5-ไตรออล และวิธีการของการใช้สิ่งเหล่านี้ | |
PE20220335A1 (es) | Composicion para la prevencion o el tratamiento de la caida del cabello que incluye hapln1 | |
CU20110041A7 (es) | Derivados de dioxa-biciclo(3.2.1)octano-2,3,4-triol | |
NZ604558A (en) | Deuterated benzylbenzene derivatives and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |